Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088010
Status:
COMPLETED
Last Update Posted:
2010-06-02
First Post:
2004-07-19
Brief Title:
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to study
Effects of arzoxifene on bone fractures and bone mass
Effects of arzoxifene on getting breast cancer
Effects of arzoxifene on certain types of cardiovascular events such as heart attack and stroke
Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health
Effects of arzoxifene on the uterus
The safety of arzoxifene and any side effects
Effects of arzoxifene on bone fractures and bone mass
Effects of arzoxifene on getting breast cancer
Effects of arzoxifene on certain types of cardiovascular events such as heart attack and stroke
Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health
Effects of arzoxifene on the uterus
The safety of arzoxifene and any side effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H4Z-MC-GJAD | OTHER | Eli Lilly and Company | None |